{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:11:27Z","timestamp":1786723887601,"version":"build-2736575974"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T00:00:00Z","timestamp":1504051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UCB BioPharma"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182887","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T17:38:39Z","timestamp":1504114719000},"page":"e0182887","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antiparkinsonian effects of the \"Radiprodil and Tozadenant\" combination in MPTP-treated marmosets"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-7903","authenticated-orcid":true,"given":"Anne","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Bri\u00f4ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sciberras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierandrea","family":"Muglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter K.","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Citron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"BS Connolly","year":"2014","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.21743","article-title":"Ten-year follow-up of Parkinson&apos;s disease patients randomized to initial therapy with ropinirole or levodopa","volume":"22","author":"RA Hauser","year":"2007","journal-title":"Mov Disord"},{"key":"ref3","first-page":"277","article-title":"Adenosine A2A receptors and basal ganglia physiology","volume":"83","author":"SN Schiffmann","year":"2007","journal-title":"ProgNeurobiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1212\/01.WNL.0000095206.44418.5C","article-title":"Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson&apos;s disease","volume":"61","author":"K Fuxe","year":"2003","journal-title":"Neurology"},{"key":"ref5","first-page":"285","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson&apos;s disease","volume":"184","author":"F Bibbiani","year":"2003","journal-title":"ExpNeurol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/1098-2396(20010301)39:3<233::AID-SYN1004>3.0.CO;2-K","article-title":"Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats","volume":"39","author":"A Pinna","year":"2001","journal-title":"Synapse"},{"key":"ref7","first-page":"8104","article-title":"In vivo characterization of a dual adenosine A2A\/A1 receptor antagonist in animal models of Parkinson&apos;s disease","volume":"53","author":"BC Shook","year":"2010","journal-title":"JMedChem"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"T Kanda","year":"1998","journal-title":"Ann Neurol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.108.149617","article-title":"Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4\u20132,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazol o[4,3-e][1, 2, 4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression","volume":"330","author":"RA Hodgson","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson&apos;s disease","volume":"102","author":"PJ Hallett","year":"2004","journal-title":"Pharmacol Ther"},{"key":"ref11","first-page":"1017","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson&apos;s disease","volume":"26","author":"S Duty","year":"2012","journal-title":"CNSDrugs"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.expneurol.2004.01.018","article-title":"Antiparkinsonian activity of Ro 25\u20136981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson&apos;s disease","volume":"187","author":"PA Loschmann","year":"2004","journal-title":"Exp Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7444","article-title":"Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson&apos;s disease","volume":"165","author":"JE Nash","year":"2000","journal-title":"Exp Neurol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1523\/JNEUROSCI.20-20-07782.2000","article-title":"A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson&apos;s disease","volume":"20","author":"JE Nash","year":"2000","journal-title":"J Neurosci"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e114086","DOI":"10.1371\/journal.pone.0114086","article-title":"Unprecedented Therapeutic Potential with a Combination of A2A\/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson&apos;s Disease","volume":"9","author":"A Michel","year":"2014","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e0135949","DOI":"10.1371\/journal.pone.0135949","article-title":"Behavioural Assessment of the A2a\/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs","volume":"10","author":"A Michel","year":"2015","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","article-title":"Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial","volume":"16","author":"HH Fernandez","year":"2010","journal-title":"ParkinsonismRelat Disord"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.22169","article-title":"Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism","volume":"23","author":"JG Nutt","year":"2008","journal-title":"Mov Disord"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0091270009336735","article-title":"Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson&apos;s disease","volume":"49","author":"C Addy","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.12688\/f1000research.10100.1","article-title":"Recent advances in treating Parkinson&apos;s disease","volume":"6","author":"WH Oertel","year":"2017","journal-title":"F1000Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1474-4422(14)70148-6","article-title":"Tozadenant (SYN115) in patients with Parkinson&apos;s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial","volume":"13","author":"RA Hauser","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref22","unstructured":"PBR SW (2010) Radiprodil Trial Fails To Show Reductions In Daily Pain Scores: Forest Labs, Gedeon Richter. In: News CT, editor. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.pharmaceutical-business-review.com\/news\/radiprodil_trial_fails_to_show_reductions_in_daily_pain_scores_forest_labs_gedeon_richter_100629\" xlink:type=\"simple\">http:\/\/clinicaltrials.pharmaceutical-business-review.com\/news\/radiprodil_trial_fails_to_show_reductions_in_daily_pain_scores_forest_labs_gedeon_richter_100629<\/ext-link>."},{"key":"ref23","first-page":"371","article-title":"Animal models of movement disorders: <italic>Neuromethods<\/italic>","author":"MJ Jackson","year":"2012"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)","volume":"10","author":"RK Pearce","year":"1995","journal-title":"Mov Disord"},{"key":"ref25","first-page":"1","article-title":"Pharmacokinetics and metabolism of [14C]-tozadenant (SYN-115), a novel A2a receptor antagonist ligand, in healthy volunteers","author":"V Mancel","year":"2016","journal-title":"Xenobiotica"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1097\/00001756-199808240-00032","article-title":"Adenosine A2A receptors modify motor function in MPTP-treated common marmosets","volume":"9","author":"T Kanda","year":"1998","journal-title":"Neuroreport"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","article-title":"Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys","volume":"52","author":"R Grondin","year":"1999","journal-title":"Neurology"},{"key":"ref28","unstructured":"Michel A, Downey P, Montel F, Scheller D, Christophe B (2013) Methods for treating parkinson&apos;s disease: Google Patents."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3758\/BF03199129","article-title":"The development of habituation in the rat","volume":"2","author":"PM Bronstein","year":"1974","journal-title":"Animal Learning & Behavior"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.neuron.2014.04.035","article-title":"Network plasticity in adaptive filtering and behavioral habituation","volume":"82","author":"M Ramaswami","year":"2014","journal-title":"Neuron"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bbr.2005.06.029","article-title":"Cocaine-conditioned activity persists for a longer time than cocaine-sensitized activity in mice: implications for the theories using Pavlovian excitatory conditioning to explain the context-specificity of sensitization","volume":"165","author":"E Tirelli","year":"2005","journal-title":"Behav Brain Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-8993(91)91399-L","article-title":"Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance","volume":"568","author":"RJ Carey","year":"1991","journal-title":"Brain Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pbb.2014.10.009","article-title":"L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson&apos;s disease model","volume":"127","author":"K Ando","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"key":"ref34","first-page":"75","article-title":"Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation","volume":"446","author":"A Pinna","year":"2002","journal-title":"EurJPharmacol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/jnc.13291","article-title":"Adenosine A(2)A receptors permit mGluR5-evoked tyrosine phosphorylation of NR2B (Tyr1472) in rat hippocampus: a possible key mechanism in NMDA receptor modulation","volume":"135","author":"K Sarantis","year":"2015","journal-title":"J Neurochem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/mol.65.1.121","article-title":"Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32","volume":"65","author":"AW Dunah","year":"2004","journal-title":"Mol Pharmacol"},{"key":"ref37","first-page":"199","article-title":"Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models","volume":"9","author":"M Ba","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbr.2014.12.059","article-title":"NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model","volume":"282","author":"M Kong","year":"2015","journal-title":"Behav Brain Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:28:35Z","timestamp":1589002115000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182887"}},"subtitle":[],"editor":[{"given":"Thomas","family":"Boraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,30]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182887","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,30]]}}}